fda warning letters glp-1 compounding september 26 2025 Trends In FY September 8, 2025: FDA launches

Oxidativestress reduction BPC-157 may also reduce oxidative stress, a harmful build-up of unstable molecules that can damage your cells and slow healing

The reported results are promising: Over 80% relative bioavailability Around 160 higher bioavailability vs oral tablets Sustained drug levels for ~1 week (once-weekly dosing potential) Additionally, the microneedle patches are stable at room temperature, eliminating the need for cold storage, unlike semaglutide injections

However, when combined with potent GLP-1 and GIP receptor activation, those glucose-raising effects are largely balanced while preserving glucagons beneficial effects on energy metabolism

Nicholas SB, Correa-Rotter R, Desai NR, et al